Abstract
Laparoscopic splenectomy (LS) has become the gold standard procedure for the treatment of benign hematological disorders not associated with splenomegaly, such as idiopathic thrombocytopenic purpura (ITP) [1, 2]. The great advances in minimally invasive surgery (MIS) that have been made over the last two decades did also benefit patients suffering from hematological malignant diseases However, this patients usually develop splenomegaly and the endoscopic manipulation of bulky organs is technically more challenging, and retrieval of the specimen may prove difficult. Splenomegaly was initially considered a contraindication for LS, thus, many malignant hematological diseases which are associated with an enlarged spleen were traditionally reserved for open splenectomy (OS) with its associated increased morbidity. Improvements and refinement of LS techniques have resulted in the ability to remove an enlarged spleen using the laparoscopic approach and preserving all the advantages of the MIS [3–5].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Park A, Targarona EM, Trias M. Laparoscopic surgery of the spleen: state of the art. Langenbecks J Surg. 2001;386:230–9.
Habermalz B, Sauerland S, Decker G, et al. Laparoscopic splenectomy: the clinical practice guidelines of the European Association for Endoscopic Surgery (EAES). Surg Endosc. 2008;22:821–48.
Weiss 3rd CA, Kavic SM, Adrales GL, et al. Laparoscopic splenectomy: what barriers remain? Surg Innov. 2005;12:23–9.
Kaban GK, Czerniach DR, Cohen R, et al. Hand-assisted laparoscopic splenectomy in the setting of splenomegaly. Surg Endosc. 2004;18:1340–3.
Targarona EM, Balagué C, Trias M. Is the laparoscopic approach reasonable in cases of splenomegaly? Semin Laparosc Surg. 2004;11:185–90.
Kant JA, Hubbard SM, Longo DL, et al. The pathologic and clinical heterogeneity of lymphocyte-depleted Hodgkin lymphoma. J Clin Oncol. 1986;4:1419–20.
Moulin-Romsee G, Hindié E, Cuenca X, et al. (18)F FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow thephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging. 2010;37:1095–105.
Jost LM, Stahel RA, ESMO Guideline Task Force. ESMO minimal clinical recommendation for diagnosis, treatment and follow up of Hodgkin’s disease. Ann Oncol. 2005;16:i54–5.
Multani P, White CA, Grillo A. Non-Hodgkin lymphoma: review of conventional treatments. Curr Pharm Biotechnol. 2001;2:279–91.
Palma M, Kokhaei P, Lundin J, et al. The biology and treatment of chronic lymphocytic leukemia. Ann Oncol. 2006;17:x144–54.
NCCN. Clinical practice guidelines in oncology™. Non-Hodgkin’s Lymphoma. V.3.2007. www.nccn.org.
Hunter T. Treatment for chronic myelogenous leukemia: the long road to imatinib. J Clin Invest. 2007;117:2036–43.
Hehlmann R, Hochhaus A, Baccarani M. European leukemia net. Chronic myeloid leukaemia. Lancet. 2007;370:342–50.
Arana-Yi C, Quintás-Cardama A, Giles F, et al. Advances in the therapy of chronic idiopathic myelofibrosis. Oncologist. 2006;11:929–43.
Dingli D, Mesa RA, Tefferi A. Myelofibrosis with myeloid metaplasia: new developments in pathogenesis and treatment. Intern Med. 2004;43:540–7.
Lopez Monclova J, Targarona Soler E, Peraza Solis Y, et al. Laparoscopic approach for isolated splenic metastasis: comprehensive literature review and report of 6 cases. Surg Laparosc Endosc Percutan Tech. 2013;23:21–4.
Heniford T, Walsh M. Laparoscopic splenectomy for malignant diseases. In: Greene FL, Heniford B, editors. Minimally invasive cancer management. 1st ed. NY: Springer; 2001. p. 143–55.
Comperat E, Bardier-Dupas A, Camparo P, et al. Splenic metastases: clinicopathologic presentation, differential diagnosis, and pathogenesis. Arch Pathol Lab Med. 2007;131:965–9.
Iwase K, Higaki J, Yoon HE, et al. Splenic artery embolization using contour emboli before laparoscopic or laparoscopically assisted splenectomy. Surg Laparosc Endosc Percutan Tech. 2002;12:331–6.
Martin Arnau B, Turrado Rodriguez V, Tartaglia E, et al. Impact of preoperative platelet count on perioperative outcome after laparoscopic splenectomy for idiopathic thrombocytopenic purpura. Cir Esp. 2016;94:399–403.
Rodriguez-Otero Luppi C, Targarona Soler EM, Balague Ponz C, et al. Clinical, anatomical, and pathological grading score to predict technical difficulty in laparoscopic splenectomy for non-traumatic diseases. World J Surg. 2017,41:439–448, doi:10.1007/s00268–016-3683-y.
Targarona EM, Balagué C, Trias M. Hand-assisted laparoscopic splenectomy. Semin Laparosc Surg. 2001;8:126–34.
Targarona EM, Balague C, Cerdan G, et al. Hand-assisted laparoscopic splenectomy (HALS) in cases of splenomegaly: a comparison analysis with conventional laparoscopic splenectomy. Surg Endosc. 2002;16:426–30.
Targarona EM, Cerdan G, Trias M. Complications of laparoscopic splenectomy. Probl Gen Surg. 2002;19:72–9.
Ikeda M, Sekimoto M, Takiguchi S, et al. High incidence of thrombosis of the portal venous system after laparoscopic splenectomy: a prospective study with contrast-enhanced CT scan. Ann Surg. 2005;24:208–16.
Targarona EM. Portal vein thrombosis after laparoscopic splenectomy: the size of the risk. Surg Innov. 2008;15:266–70.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
1 Electronic Supplementary Materials
Hand assisted splenectomy (HALS) (MPG 23982 kb)
Hand assisted splenectomy (HALS). Targarona (MP4 374061 kb)
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Monclova, J.L., Luppi, C.R., Targarona Soler, E.M. (2017). Minimally Invasive Splenectomy for Oncological Diseases of the Spleen. In: Cuesta, M. (eds) Minimally Invasive Surgery for Upper Abdominal Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-54301-7_32
Download citation
DOI: https://doi.org/10.1007/978-3-319-54301-7_32
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-54300-0
Online ISBN: 978-3-319-54301-7
eBook Packages: MedicineMedicine (R0)